Precision Oncology: 2022 in Review.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
02 12 2022
02 12 2022
Historique:
entrez:
2
12
2022
pubmed:
3
12
2022
medline:
6
12
2022
Statut:
ppublish
Résumé
This article presents a review of the major advances and future implications in precision oncology accomplished in 2022 and centers on three primary pillars: advances in (i) rational drug design, (ii) study design, and (iii) novel biomarkers.
Identifiants
pubmed: 36458431
pii: 711165
doi: 10.1158/2159-8290.CD-22-1154
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2747-2753Informations de copyright
©2022 American Association for Cancer Research.